CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 73 enrolled
Drug / intervention
Rifaximindrug
Likely dose
Rifaximin 550 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01466595
NCT01466595Phase 2Completed
CompareCT.gov

A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections·interventional·Posted Nov 8, 2011·Updated Sep 10, 2018

In Brief

A Phase 2 clinical trial evaluating Rifaximin for HIV-1 Infection. Completed, enrolled 73 participants across 32 sites in 2 countries.

Detailed Summary

This study is being done to see whether rifaximin, an antibiotic that works in the intestines, can lower the amount of germs in the intestines of HIV infected persons. It is possible that when the amount of these germs is lowered, an HIV-infected person's immune system will become less active and will have a better chance of recovering. Also, the study will evaluate the safety of using rifaximin in HIV-infected subjects.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV-1 Infection
CountriesPuerto Rico, United States
CollaboratorsNational Institute of Allergy and Infectious Diseases (NIAID)

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedNov 8, 2011
Enrollment StartSep 1, 2011
Primary CompletionSep 1, 2012
Study CompletionNov 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 14.7 years ago

Interventions

Rifaximindrug

Participant were administered one 550 mg tablet of rifaximin to be taken orally two times a day for 4 weeks.